Safety of Lower Scalp Cooling Temperature to Prevent Hair Loss From Chemotherapy in Breast Cancer Patients

Inclusion Criteria: * Age 18 years or older * New diagnosis of breast cancer stage I-IV * Planning to undergo neoadjuvant or adjuvant chemotherapy with curative intent * Chemotherapy must be planned for at least 4 cycles of full-dose anthracycline plus cyclophosphamide followed by taxane based chemotherapy regimen: * Concurrent trastuzumab at standard doses is allowed * Concurrent pertuzumab at standard doses is allowed * Administration of chemotherapy on a dose dense schedule is allowed as clinically indicated * For women of childbearing potential, a negative pregnancy test is needed within 7 days prior to study intervention, or whenever collected as per standard of care. For women who undergo fertility preservation or ovarian stimulation, a negative pregnancy test is not needed and eligibility due to positive pregnancy test will be determined by investigator discretion. Exclusion Criteria: * Any other concurrent malignancy including hematological malignancies (i.e. leukemia or lymphoma) * Baseline alopecia (defined CTCAE v5.0 grade \> 1) * Subjects who are scheduled for bone marrow ablation chemotherapy * Male gender * Age \>/= 75 years * Personal history of migraines, cluster or tension headaches as defined as actual medical diagnosis by a physician and/or prescribed medications. If personal history of migraines was related to a past medical problem that is now resolved, subject may go on study at the discretion of the Principal Investigator. * Subjects who have had prior chemotherapy * Subjects who have had \>/=1 previous chemotherapy exposure resulting in alopecia * An existing history of scalp metastases or suspected presence of scalp metastasis * Subjects with cold sensitivity, cryoglobulinemia, cryofibrinogenemia, or cold migraine pot-traumatic cold dystrophy * Previously received, or scheduled to undergo skull irradiation